Eli Lilly plans to acquire psychedelics specialist AtaiBeckley through a multibillion-dollar deal that shows big pharma’s growing endorsement of a once-dimissed, now rapidly emerging research field.
Per deal terms, Lilly will pay $6.75 up front for each share of the New York-based biotechnology company, reflecting a 26% premium and an equity value of approximately $2.8 billion. AtaiBeckley investors will also receive so-called contingent value rights that could be worth up to $2.50 a share depending on whether select drug programs hit certain milestones. The total value could therefore hover around $3.8 billion.
The companies expect to close their deal before the end of September. If completed, the acquisition would hand Lilly a few experimental drugs that have moved into human studies. The most advanced of those, codenamed BPL-003, just entered late-stage testing as a potential therapy for hard-to-treat depression. BPL-003 is a version of mebufotenin — a molecular cousin to psilocybin, the psychedelic compound found in some mushroom species. A mid-sized study found that a single dose of the drug quickly reduced symptoms of treatment-resistant depression.
AtaiBeckley’s other programs are based on compounds like MDMA and DMT. The company was formed in late 2025, when Atai Life Sciences acquired Beckley Psytech.
Christian Angermayer, who founded Atai and is now board chairman and largest shareholder of the combined company, said in a statement that Lilly, with its resources and scale, has to potential to “advance therapies faster than we could alone.”
“I am confident this transaction represents the best path forward for patients and shareholders," Angermayer said.
As for Lilly, the deal offers an entryway into psychedelics and further diversifies its neuroscience division. This spring, the company agreed to buy Centessa Pharmaceuticals for $6.3 billion to join another budding area of drug development: a new class of sleep medicine that Wall Street foresees generating billions of dollars in sales.
Prior to Lilly’s buyout, the biggest psychedelics deals were Otsuka Pharmaceutical’s $700 million acquisition of Transcend Therapeutics, whose lead drug is an analog of MDMA, and an asset purchase from AbbVie worth possibly more than $1 billion.
At Jefferies, analyst Andrew Tsai expects psychedelics "to garner even more mindshare" as developers deliver more positive data from larger, placebo-controlled trials that can support FDA approvals. "We think the various pieces across the clinical, regulatory and commercial fronts are coming together," he wrote in a note to clients.
Paul Matteis, an analyst at the investment firm Stifel, views the AtaiBeckley deal as “highly validating for the psychedelic space” and a positive for fellow developers like Compass Pathways and Definium Therapeutics, each of which reported positive data from depression studies this year. Having a large, deep-pocketed player like Lilly in the market “should help build out the delivery model for these medicines, which remains the biggest challenge/impediment to uptake,” he wrote.
Matteis added that investors have frequently questioned whether big pharma would be interested in psychedelics, a research area which historically faced significant pushback from both the government and scientific institutions. Yet, perceptions around these mind-altering compounds have substantially changed in the last decade. Not only has the Food and Drug Administration provided developers with guidance on how to best study psychedelics — the latest of which came this week — but Johnson & Johnson has proven that companies can find commercial success here. Its product Spravato, a form of ketamine used for treatment-resistant depression, brought in almost $1.1 billion during the first half of this year, a 43% increase from the same period in 2025.
“[I]t's become increasingly clear to us that this will likely be a category with multiple blockbuster products,” Matteis wrote.
In his own note, RBC Capital Markets analyst Trung Huynh wrote that the AtaiBeckley deal is a "strategically coherent extension" of Lilly's neuroscience franchise and consistent with the pharmaceutical giant's "broader land grab M&A strategy."
Cash-rich from its massive obesity drug business, Lilly has been on a dealmaking tear the past couple years, snapping up experimental medicines for cancer, infectious disease, cardiovascular conditions and immune system disorders. So far this year, Lilly has acquired 11 fellow drugmakers, by far the most among its pharmaceutical peers, according to BioPharma Dive data.
